El rol de la vacuna frente al virus del papiloma humano, una forma diferente de prevención.

Abstract

More than 10 years have passed since the first prophylactic vaccine against the human papilloma virus is available, knowing that it is the etiological agent for the development of cervical cancer and responsible for the third cause of death worldwide. The first two vaccines that are of the first generation have been successful, although one is bivalent covering type 6 -11 and the other is tetravalent that covers types 6 - 11 - 16 - 18; Hundreds of millions of women and a much smaller number of men have been vaccinated since then. Knowing and knowing that the range of being infected by a high-risk HPV serotype is 60-80%. The clinical impact of vaccination programs is already visible worldwide and Ecuador is not far behind, although it only offers free of charge to girls, but they are still commercialized with high and variable costs between the two vaccines. The Gardasil9, which covers types 6, 11, 16, 18, 31, 33, 45, 52, 58, is one of the last vaccines, being of second generation particles similar to the HPV virus that was authorized in 2014, which covers more serotypes of the human papillomavirus. Currently, the issues with the HPV vaccine is the age of application, the duration of protection, the number of doses; and its adverse effects whether local or systemic.